Browse the evidence

The 5:2 total diet replacement (5:2TDR) resulted in a weight loss of -0.9 kg after 26 weeks, while the once-daily meal-replacement (DMR) group experienced a weight regain of 3.5 kg, leading to a between-group difference of -4.4 kg.

Practitioners may consider recommending 5:2TDR for better weight maintenance outcomes compared to DMR.

Both dietary interventions (5:2TDR and DMR) maintained weight losses greater than 15 kg below baseline at 26, 52, and 78 weeks.

Both interventions can be effective for long-term weight maintenance.

At 5-6 months, the mean weight reduction was 7.9%, with 56% of participants achieving more than 5% weight loss.

Phentermine/topiramate ER can be effective for weight loss in obese patients.

At 12 months, patients who persisted in treatment experienced an average weight loss of 9.6%, with 65% surpassing a 5% weight loss.

Long-term adherence to treatment can lead to significant weight loss.

Participants at the intervention sites lost significantly more weight (−8.0±6.7 kg) compared to control sites (+0.6±2.8 kg, p<0.0001).

Worksite interventions can effectively promote weight loss among employees.

The intervention led to significant improvements in systolic blood pressure (−8.6±12.6 mmHg) compared to control (+5.5±10.8 mmHg, p<0.0001).

Worksite interventions can lead to better blood pressure management.

Efsubaglutide Alfa produced a mean weight reduction of 7.16% versus 0.86% with placebo.

Efsubaglutide Alfa may be an effective treatment option for weight loss in individuals with obesity or overweight.

82.5% of Efsubaglutide-treated participants achieved ≥5% weight loss.

A significant proportion of individuals treated with Efsubaglutide Alfa can expect to achieve clinically meaningful weight loss.

Cagrisema produced significantly greater percentage weight loss than semaglutide with a mean difference of -7.47% (95% CI: -10.58, -4.36; p < 0.001).

Cagrisema may be a more effective option for weight loss in obese patients compared to semaglutide.

Cagrilintide monotherapy weight loss was comparable to semaglutide.

Cagrilintide may be a viable alternative to semaglutide for weight management in obese patients.

Cagrisema is safe and has a comparable side effect profile to semaglutide.

Cagrisema can be considered a safe option for weight management in obese patients.

Meal replacements (MRs) led to a greater reduction in body weight by -1.38 kg compared to conventional food-based weight loss diets.

Incorporating meal replacements can be an effective strategy for weight loss in individuals at risk of metabolic syndrome.

MRs resulted in a reduction in body mass index (BMI) by -0.56 kg/m2 compared to conventional diets.

Using meal replacements can help reduce BMI in at-risk populations.

The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo.

Semaglutide may lead to significant weight loss in patients with MASH.

Participation in high-intensity programs for 6 months can lead to weight loss of up to 8 kg (8% of weight) and improvements in cardiovascular disease risk factors and quality of life.

Clinicians should recommend high-intensity lifestyle modification programs for effective weight loss.

To prevent weight regain, participation in weight-loss-maintenance programs for 1 year with at least monthly counseling is recommended.

Clinicians should implement long-term maintenance strategies to support weight loss sustainability.

High levels of physical activity, frequent monitoring of body weight, and consumption of a reduced-calorie diet are associated with long-term weight loss.

Encourage patients to maintain high physical activity and monitor their weight regularly for effective weight management.

Intensive lifestyle modification decreased the incidence of diabetes by 6.2 cases per 100 person-years during a 3-year period.

Encouraging lifestyle changes can significantly reduce the risk of developing diabetes.

Treatment with once-weekly injectable semaglutide resulted in a mean change in body weight of -13.7% compared to -3.2% with placebo (P<0.001).

Semaglutide may be an effective treatment for weight loss in obese individuals with knee osteoarthritis.

Higher weight loss was associated with a lower hazard of discontinuation for both patients with and without type 2 diabetes.

Encouraging weight loss may improve adherence to GLP-1 RA therapy.

Habit formation interventions have shown promising effects on behavior.

Incorporating habit formation techniques can enhance the effectiveness of behavior change programs.

Habit formation interventions may help displace existing bad habits with good ones.

Practitioners can utilize habit formation strategies to replace negative behaviors with positive ones.

Participants in the highest category for total whole grain consumption had a 29% lower rate of type 2 diabetes compared with those in the lowest category.

Encouraging higher whole grain consumption can be an effective strategy for reducing the risk of type 2 diabetes.

Pooled hazard ratios for type 2 diabetes were 0.81 for whole grain cold breakfast cereal and 0.79 for dark bread when comparing those consuming one or more servings a day to those consuming less than one serving a month.

Incorporating whole grain cold breakfast cereal and dark bread into the diet may significantly lower diabetes risk.